灯盏细辛与复方丹参注射液治疗脑梗死疗效比较的Meta分析

Efficacy of Erigeron breviscapus Injection versus Compound Salvia miltiorrhiza Injection in Treatment of Cerebral Infarction:A Meta-Analysis

目的系统评价灯盏细辛对比复方丹参治疗脑梗死的疗效。方法计算机检索中国期刊全文数据库、中国生物医学文献数据库、万方数据库和维普数据库,并辅以手工检索和其他检索,收集灯盏细辛治疗脑梗死的随机对照试验,检索时间截至2013年7月。由2名研究者按照纳入与排除标准独立筛选文献、提取资料,并采用Jadad量表对纳入研究进行质量评价后,用RevMan 5.0软件进行Meta分析。结果共纳入23个随机对照试验。Meta分析结果显示,灯盏细辛改善神经缺损的效果优于复方丹参,灯盏细辛对脑梗死的有效率高于复方丹参,灯盏细辛的不良反应轻微。结论灯盏细辛可有效治疗脑梗死,其效果优于复方丹参,不良反应轻微。

Objective To evaluate the efficacy of Erigeron breviscapus versus compound Salvia miltiorrhiza in the treatment of cerebral infarction by a systematic review. Methods Randomized controlled trials （RCTs） of Erigeron breviscapus in the treatment of cerebral infarction published up to July 2013 were collected by searching CNKI, CBM, Wanfang Data, and VIP, as well as other materials. Two researchers independently screened studies according to inclusion and exclusion criteria and then extracted data. The quality of included studies was assessed by Jadad scale. A meta-analysis was performed using RevMan 5.0. Results A total of 23 RCTs were included. Compared with the compound Salvia miltiorrhiza group, the Erigei：on breviscapus group had a more improvement in neurological deficit, a higher response rate, and milder adverse reactionS. Conclusion Erigeron breviscapus is effective in treating cerebral infarction and has better efficacy than compound Salvia miltiorrhiza, and it has little adverse effect.